SFN and lung carcinoma: In the DAD group, there were no significant differences in the levels of SFN among patients with lung cancer, other tissue cancers, and non-cancerous diseases, and no significant differences among patients treated with the different classes of suspected drugs (Supplementary Fig. 4a and d); in fact, the SFN-positivity rates (>3.6 ng/mL) were almost equivalent among the groups (Supplementary Tables 10 and 11).